Journal List > J Korean Rheum Assoc > v.15(2) > 1003612

TOOLS
Baek, Lee, Kim, Lee, Cho, Kim, Lee, Kim, and Kim: Increased Interleukin-17 Expression in Patients with Idiopathic Inflammatory Myopathies
Original Article

J Korean Rheum Assoc 2008;15(2):118-122.

Published online: 20 March 2008

DOI: https://doi.org/10.4078/jkra.2008.15.1.118

Increased Interleukin-17 Expression in Patients with Idiopathic Inflammatory Myopathies

Seung-Hoon Baek∗∗∗, Jun-Hee Lee, Geun-Tae Kim, Joung-Wook Lee, Mi-Ra Cho, Ju-In Kim∗∗, Sun-Hee Lee, Dae-Seong Kim∗, Sung-Il Kim

Department of Internal Medicine, College of Medicine, Pusan National University, Busan, Korea

∗Department of Neurology, College of Medicine, Pusan National University, Busan, Korea

∗∗Department of Research Institute, College of Medicine, Pusan National University, Busan, Korea

∗∗∗Department of Internal Medicine, Busan St. Mary's Medical Center, Busan, Korea

Received 3 January 2008       Revised 27 March 2008

Copyright © 2008 The Korean Rheumatism Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective

Idiopathic inflammatory myopathies (IIMs) are systemic autoimmune diseases characterized by infiltration of T lymphocytes, monocytes, and macrophages in muscle tissues. Interleukin-17 (IL-17), a Th17 cytokine, has potent pro-inflammatory actions and plays a role in autoimmune diseases. We investigated the expression of IL-17 in muscle tissues of patients with IIMs.

Methods

We measured the IL-17 mRNA level of muscle tissues from 14 patients with IIMs (9 patients with dermatomyositis and 5 patients with polymyositis) by real-time RT-PCR and compared with controls. We also performed an immunohistochemical stain to detect IL-17 expression.

Results

The expressions of IL-17 were significantly enhanced in IIMs than controls. In immunohistochemistry, IL-17 was expressed in perimysial, endomysial and perivascular infiltrating inflammatory cells.

Conclusion

These results suggest that IL-17 plays a role in the immunopathogenesis of IIMs.

Keywords: Interleukin-17, Idiopathic inflammatory myopathies, Dermatomyositis, Polymyositis

References

1. Briani C, Doria A, Sarzi-Puttini P, Dalakas MC. Update on idiopathic inflammatory myopathies. Autoimmunity. 2006; 39:161–70.
crossref
2. Wiendl H, Hoflfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trend Immunol. 2005; 26:373–80.
crossref
3. Salomonsson S, Lundberg I. Cytokines in idiopathic inflammatory myopathies. Autoimmunity. 2006; 39:177–90.
crossref
4. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007; 8:913–9.
crossref
5. Toh ML, Miossec P. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol. 2007; 19:284–8.
crossref
6. Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P. Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol. 2003; 137:125–33.
7. Page G, Chevrel G, Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis. Arthritis Rheum. 2004; 50:199–208.
8. Baird GS, Montine TJ. Multiplex immunoassay anlysis of cytokines in idiopathic inflammatory myo-pahty. Arch Pathol Lab Med. 2008; 132:232–8.
9. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292:403–7.
10. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292:403–7.

Fig. 1.
Immunohistochemistry of IL-17 in muscle tissues from patients with IIMs (B, C) and control (A). In DM (B) and PM (C), IL-17 was expressed in perimysial, endomysialand perivascular infiltrating inflammatory cells (arrow). Muscle tissue from control was negative (A). Magnification, ×200. IIMs: idiopathic inflammatory myopathies, DM: dermatomyositis, PM: polymyositis.
jkra-15-118f1.tif
Table 1.
Demographic, clinical, and laboratory characteristics in 14 patients with idiopathic inflammatory myopathies
Patient/Sex Age Diagnosis Disease duration (months) CK, units/L Anti-Jo-1 Antibody Relative levels of IL-17 compared to controls
1/F 66 DM 1 3,969 negative 39.3
2/M 36 DM 3 2,815 positive 67.6
3/M 42 DM 2 1,163 negative 18.4
4/M 40 DM 12 70 negative 26.9
5/M 58 DM 1 3,006 negative 8.8
6/M 42 DM 2 ＞6,000 negative 18.7
7/M 56 DM 1 3,034 negative 62.2
8/F 36 DM 6 ＞6,000 negative 100.0
9/F 19 DM 3 668 not checked 122.0
10/F 51 PM 2 ＞6,000 negative 75.4
11/M 25 PM 3 32 negative 21.8
12/F 62 PM 1 2,207 positive 139.0
13/F 34 PM 7 2,743 positive 218.0
14/F 43 PM 1 1,820 negative 10.5
  43.6±13.7   3.2±3.1 2,823±2,072   66.3±60.6

CK: creatinine kinase (normal＜160 units/liter), DM: dermatomyositis, PM: polymyositis

TOOLS
Similar articles